Shinzato H, Koda M, Nakamura A, Kondo T.Development of the 12-item questionnaire for quantitative assessment of depressive mixed state (DMX-12).
Neuropsychiatr Dis Treat. 2019 Jul 15;15:1983-1991
Suzuki T, Mihara K, Nagai G, Kagawa S, Nakamura A, Nemoto K, Kondo T.
Relationship Between UGT1A4 and UGT2B7 Polymorphisms and the Steady-State Plasma Concentrations of Lamotrigine in Patients With Treatment-Resistant Depressive Disorder Receiving Lamotrigine as Augmentation Therapy.
Ther Drug Monit. 2019 Feb;41(1):86-90
Nakamura A, Mihara K, Nagai G, Sakumoto N, Kondo T.
Serum creatine kinase elevation by atypical antipsychotics and genetic polymorphisms of the 5-HT2A receptor and the cytochrome P4502D6
Clinical Neuropsychopharmacology and Therapeutics 2018(9): 3-6
Nagai G, Mihara K, Kagawa S, Nakamura A, Suzuki T, Nemoto K, Kondo T.
A Partial Response at Week 4 Can Predict Subsequent Outcome during Lamotrigine Augmentation Therapy in Treatment-Resistant Depressive Disorder: A Preliminary Study.
Neuropsychobiology. 2017;76(4):187-192
Kagawa S, Mihara K, Suzuki T, Nagai G, Nakamura A, Nemoto K, Kondo T.
Both Serum Brain-Derived Neurotrophic Factor and Interleukin-6 Levels Are Not Associated with Therapeutic Response to Lamotrigine Augmentation Therapy in Treatment-Resistant Depressive Disorder.
Neuropsychobiology. 2017;75(3):145-150
①Nagai G, Mihara K, Nakamura A, Nemoto K, Kagawa S, Suzuki T, Kondo T.
Prediction of an Optimal Dose of Aripiprazole in the Treatment of Schizophrenia From Plasma Concentrations of Aripiprazole Plus Its Active Metabolite Dehydroaripiprazole at Week 1
Ther Drug Monit. 2017 Feb, 39(1):62-65.
②Nakamura A, Mihara K, Nagai G, Kagawa S, Suzuki T, Nemoto K, Kondo T.
Ther Drug Monit. 2017 Feb, 39(1):62-65.
②Nakamura A, Mihara K, Nagai G, Kagawa S, Suzuki T, Nemoto K, Kondo T.
Prediction of an Optimal Dose of Lamotrigine for Augmentation Therapy in Treatment-Resistant Depressive Disorder From Plasma Lamotrigine Concentration at Week 2.
Ther Drug Monit. 2016 Jun;38(3):379-82.
③Mihara K, Nakamura A, Nemoto K, Nagai G, Kagawa S, Suzuki T, Kondo T.
Ther Drug Monit. 2016 Jun;38(3):379-82.
③Mihara K, Nakamura A, Nemoto K, Nagai G, Kagawa S, Suzuki T, Kondo T.
Lamotrigine augmentation therapy in a case with treatment-resistant unipolar depression that showed insufficient response to electroconvulsive therapy.
Psychiatry Clin Neurosci. 2016 Feb;70(2):126.
④Nakamura A, Mihara K, Nemoto K, Nagai G, Kagawa S, Suzuki T, Kondo T: 2014, Lack of correlation between the steady-state plasma concentrations of aripiprazole and haloperidol in Japanese patients with schizophrenia.
Ther Drug Monit. 2014 Apr 15.
⑤Nemoto K, Mihara K, Nakamura A, Nagai G, Kagawa S, Suzuki T, Kondo T. 2014, Effects of escitalopram on plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole in Japanese patients. Pharmacopsychiatry 47: 101-104.
⑥Suzuki T, Mihara K, Nakamura A, Nagai G, Kagawa S, Nemoto K, Kondo T. 2014, Effects of genetic polymorphisms of CYP2D6, CYP3A5, and ABCB1 on the steady-state plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia. Ther Drug Monit. 2014 Mar 27.
⑦Kagawa S, Mihara K, Nakamura A, Nagai G, Suzuki T, Nemoto K, Kondo T. 2014, Relationship between plasma concentrations of lamotrigine and its early therapeutic effect of lamotrigine augmentation therapy in treatment-resistant depressive disorder. Ther Drug Monit. 2014 May 9.
⑧Nagai G, Mihara K, Nakamura A, Suzuki T, Nemoto K, Kagawa S, Ohta I, Arakaki H, Kondo T, 2012, Prolactin concentrations during aripiprazole treatment in relation to sex, plasma drugs concentrations and genetic polymorphisms of dopamine D2 receptor and cytochrome P450 2D6 in Japanese patients with schizophrenia. Psychiatry and Clinical Neurosciences 66: 518-524.
⑨Nemoto K, Mihara K, Nakamura A, Nagai G, Kagawa S, Suzuki T, Kondo T, 2012, Effects of paroxetine on plasma concentrations of aripiprazole and its active metabolite, dyhydroaripiprazole, in Japanese patients with schizophrenia. Ther Drug Monit 30: 188-192.
⑩Suzuki T, Mihara K, Nakamura A, Nagai G, Kagawa S, Nemoto K, Ohta I, Arakaki H, Uno T, Kondo T, 2011, Effects of the CYP2D6*10 allele on the steady-state plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia. Ther Drug Monit 33: 21-4.
⑪Kagawa S, Nemoto K, Suzuki T, Nagai G, Nakamura A, Mihara K, Kondo T, 2010, Lamotorigine augmentation for the treatment-resistant mood disorder. Clinical Neuropsychopharmacology and Therapeutics 1: 35-42
⑫Mihara K, Nagai G, Nakamura A, Fukuji Y, Suzuki T, Kondo T. 2010, Improvement in antipsychotic-induced hyperprolactinemia with the addition of aripiprazole in schizophrenic patients. Clinical Neuropsychopharmacology and Therapeutics 1: 1-5
⑬Nakamura A, Mihara K, Nagai G, Suzuki T, Kondo T. 2009, Pharmacokinetic and pharmacodynamic interactions between carbamazepine and aripiprazole in patients with schizophrenia. Ther Drug Monit. 31(5):575-8.
⑭Nagai G, Ono S, Yasui-Furukori N, Nakamura A, Mihara K, Kondo T. 2009, Formulations of valproate alter valproate metabolism: a single oral dose kinetic study. Ther Drug Monit. 31(5):592-6.
⑮Shen HM, Nakamura A, Sugimoto J, Sakumoto N, Oda T, Jinno Y, Okazaki Y. 2006, Tissue specificity of methylation and expression of human genes coding for neuropeptides and their receptors, and of a human endogenous retrovirus K family. J Hum Genet. 51(5):440-50.
⑯Nakamura A, Okazaki Y, Sugimoto J, Oda T, Jinno Y. 2003, Human endogenous retroviruses with transcriptional potential in the brain. J Hum Genet. 48(11):575-81.
